When genes are expressed at the wrong time or in the wrong amounts, it alters the function of a cell, leading to disease. By developing small-molecule medicines to control gene expression, we aim to make a profound difference in patients’ lives. We are currently developing tamibarotene for genomically defined subsets of MDS and AML patients. These are cancers that have largely eluded other genomics-based approaches.